Sanofi hoping to convert patients to Toujeo as Lantus is due to lose U.S. patent protection. (Find the full prescribing info for Toujeo at the bottom of this article.)….
Toujeo is a more potent follow-up to the drugmaker’s top-selling Lantus insulin product, which accounts for a fifth of Sanofi sales. The U.S. Food and Drug Administration late last week approved the once daily, long-acting basal insulin to treat type 1 and type 2 diabetes.
Analysts noted, however, that lower rates of hypoglycemia seen in clinical trials comparing Toujeo to Lantus, were not mentioned on the FDA-approved label. It also highlighted the need for higher doses to achieve the same level of blood glucose control as Lantus.
The Toujeo label is probably going to be viewed as more undifferentiated than expected.
Sanofi bought some patient conversion time with a patent infringement lawsuit filed last year against Eli Lilly and Co that keeps a cheaper Lantus generic off the market for 30 months.
In addition to gaining patients through conversions, there are about a million new patients for basal insulin each and every year.
Toujeo has the same active ingredient as Lantus, called insulin glargine, but at three times the concentration and with a design to release the insulin more gradually. Lantus is the world’s most prescribed insulin.